Christopher Ogden - 13 Jun 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTMX
Reported as of: 13 Jun 2025
Net transaction value: -$33,381
SEC form: 4
Accepted by SEC: 17 Jun 2025, 16:11:18 UTC
Prior SEC filing: 20 Mar 2025
Next SEC filing: 30 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden

Key filing fact

Christopher Ogden filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 17 Jun 2025.

Key facts

This page summarizes Christopher Ogden's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2025, 16:11.

Change

Previous filing in this sequence was filed on 20 Mar 2025.
Current net transaction value: -$33,381.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914523 Primary reporting owner

Ogden Christopher

Relationship: Chief Financial Officer
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Signature date: 17 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTMX transaction

Common Stock

Sale

Transaction value: $4,841
Shares: -1,641
Change %: -0.82%
Price: $2.95
Shares after: 199,385
Date: 13 Jun 2025
Ownership: Direct
Footnotes: F1, F2

CTMX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +37,500
Change %: +19%
Price: $0.000000
Shares after: 236,885
Date: 13 Jun 2025
Ownership: Direct
Footnotes: F2, F3

CTMX transaction

Common Stock

Sale

Transaction value: $28,540
Shares: -10,614
Change %: -4.5%
Price: $2.69
Shares after: 226,271
Date: 16 Jun 2025
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Performance Stock Units

Options Exercise

Transaction value: $0
Shares: -37,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 13 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Footnote F2

Includes 149,987 RSUs.

Footnote F3

This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.

Footnote F4

The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.

Footnote F5

Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.